Shanghai Medicilon, Inc.SSE: 688202

Announcement on Progress of Litigation Involving the Subsidiary

· Issued by Shanghai Medicilon, Inc. via Shanghai Stock Exchange

Filed with SSE · · 3 pages · Chinese

Summary by 6ix AI

Shanghai Medicilon, Inc. has announced the progress of litigation involving its subsidiary, Medicilon Puyuan Pharmaceutical Technology (Shanghai) Co., Ltd. The announcement details the basic situation of the lawsuit, including the judgment and withdrawal of counterclaims. The court ruled that the subsidiary must pay a specified amount to the plaintiff, while other claims were dismissed. The company warns that the case may proceed to a second trial, urging investors to be aware of potential risks.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Shanghai Medicilon, Inc. on 6ix

Earlier from Shanghai Medicilon

Later from Shanghai Medicilon

All Shanghai Medicilon news releases